Free tool · No account
Clinical trials for lymphoma
Lymphoma trials divide sharply between Hodgkin and the many non-Hodgkin subtypes, and between newly diagnosed and relapsed disease. The specific subtype is the most useful thing to include.
1,646 recruiting trials. Showing a sample.
- recruitingNCT03911128
A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
The pilot study collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new platform protocol, which is both a comprehensive system for stratification and treatment of ALL in ...
Listed by the study for Precursor Cell Lymphoblastic Leukemia-Lymphoma. Record updated 2026-08-13.
Sponsored by Mats HeymanFull details on ClinicalTrials.gov → - recruitingEARLY_Phase 1NCT04603872
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Listed by the study for Non-Hodgkin's Lymphoma, Relapsed. Record updated 2020-10-28.
Sponsored by Zhejiang UniversityFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT03938987
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).
Listed by the study for Relapsed Non Hodgkin Lymphoma. Record updated 2026-02-09.
Sponsored by University of AlbertaFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT04390737
Evaluate the Safety and Clinical Activity of HH2853
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.
Listed by the study for FL Lymphoma. Record updated 2026-01-30.
Sponsored by Haihe Biopharma Co., Ltd.Full details on ClinicalTrials.gov → - recruitingEARLY_Phase 1NCT05093335
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic ...
Listed by the study for Non-Hodgkin Lymphoma. Record updated 2026-02-05.
Sponsored by Memorial Sloan Kettering Cancer CenterFull details on ClinicalTrials.gov → - recruitingNCT06796517
Immunotherapy in Lymphoma
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is: Does advanced immunochemotherapy, including CAR...
Listed by the study for Relapsed/refractory High Grade B Cell Lymphoma. Record updated 2025-01-28.
Sponsored by Sung-Soo ParkFull details on ClinicalTrials.gov → - recruitingPhase 1NCT05798897
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
Listed by the study for Non-Hodgkin Lymphoma, Adult. Record updated 2026-09-15.
Sponsored by Marker Therapeutics, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT04752826
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how sa...
Listed by the study for T-cell Lymphoma. Record updated 2026-09-18.
Sponsored by BioInvent International ABFull details on ClinicalTrials.gov → - recruitingPhase 2NCT07507318
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
This is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL) who achieve complete response after induction th...
Listed by the study for Diffuse Large B-Cell Lymphoma. Record updated 2026-06-18.
Sponsored by Rong TaoFull details on ClinicalTrials.gov → - recruitingNCT06782789
An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
The study is pilot, observational, retrospective, Italian multicenter study.
Listed by the study for Diffuse Large B Cell Lymphoma (DLBCL). Record updated 2025-01-20.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di BolognaFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-10-12. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this lymphoma trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.